Kunutsor, S. K., Whitehouse, M. R., Blom, A. W., & Laukkanen, J. A. (2017). Statins and venous thromboembolism: do they represent a viable therapeutic agent? *Expert Review of Cardiovascular Therapy*, 15(8), 629-637. <https://doi.org/10.1080/14779072.2017.1357468>

Peer reviewed version

Link to published version (if available):
[10.1080/14779072.2017.1357468](https://doi.org/10.1080/14779072.2017.1357468)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Taylor & Francis at <http://www.tandfonline.com/doi/full/10.1080/14779072.2017.1357468>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Statins and venous thromboembolism: do they represent a viable therapeutic agent?

Setor K. Kunutsor, MD, PhD¹, Michael R. Whitehouse, PhD, FRCS¹, Ashley W. Blom, MD, PhD, FRCS¹, Jari A. Laukkanen, MD, PhD^{2,3}

¹School of Clinical Sciences, University of Bristol, Learning & Research Building (Level 1), Southmead Hospital, Southmead, BS10 5NB, UK

²Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland

³Central Finland Central Hospital, Jyväskylä, Finland

Correspondence:

Setor K. Kunutsor, Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Learning & Research Building (Level 1), Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK; Phone: +44_7539589186; Fax: +44-1174147924

Email address: skk31@cantab.net

Abstract

Introduction: Venous thromboembolism (VTE) is an important cause of preventable morbidity and mortality. Though anticoagulants are effective in preventing VTE, they are associated with major bleeding risk. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (known as statins), are well established for the primary and secondary prevention of cardiovascular disease via their lipid-lowering properties. Emerging evidence suggests that statins may play a role in the prevention of VTE, but the evidence has been uncertain.

Areas covered: This review summarizes the available epidemiological and interventional evidence on the role of statins in VTE prevention; the postulated biologic mechanisms involved; outlines areas of outstanding uncertainty; and the implications for clinical practice.

Expert commentary: The body of evidence indicates statins may also play a potential role in the primary and secondary prevention of VTE. Further evidence is however warranted. There is insufficient evidence to recommend the use of statins to replace anticoagulants in VTE prevention. However, guideline bodies should review the overall evidence and consider including statin therapy as an adjunct to anticoagulant therapy in VTE prevention in specific patient populations. Statin therapy instead of anticoagulants may be considered in patients who are not candidates for anticoagulant therapy and in some low VTE risk patients.

KEYWORDS: Statins; venous thromboembolism; deep vein thrombosis; pulmonary embolism; prevention

1. Introduction

Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE); DVT is the most frequent presentation of VTE, while PE is the most serious clinical presentation of VTE. Venous thromboembolism affects several millions of people worldwide.

Globally, VTE has an annual incidence of 100-200 per 100,000 inhabitants and it is the third most common cardiovascular disease (CVD).[1, 2] In Europe alone, approximately 1.1 million VTE events occur each year and cause more than half a million deaths;[3, 4] while in the US, VTE events affect about 900,000 people annually, with up to 300,000 deaths.[3] Apart from being a preventable cause of deaths, VTE is an important cause of morbidity and associated with substantial healthcare costs.[4, 5] Though VTE is quite common in the elderly, major risk factors for VTE include major surgery such as lower limb total joint replacement, active cancer with or without concurrent chemotherapy, neurological disease with paresis of the lower limbs, prolonged bed stay as a result of hospitalization or nursing home confinement, trauma or fracture of lower limbs, oral contraception, and hormone replacement therapy (HRT).[4]

Primary and secondary prevention of VTE can be achieved by pharmacological and/or physical means. In primary prevention, pharmacological prophylaxis for VTE includes the use of low, fixed doses of anticoagulants such as unfractionated heparin, low-molecular weight heparin (LMWH), warfarin, or fondaparinux. For patients undergoing lower limb orthopaedic surgery (eg, total knee or hip replacement), novel oral anticoagulants (NOACs) (such as edoxaban, dabigatran, rivaroxaban, or apixaban) are available to use instead of heparin, warfarin, or fondaparinux.[6] Physical or mechanical measures such as graduated compression stockings, use of lower extremity compression devices, patient mobility, and rehabilitation are also considered in addition to these thromboprophylactic agents or are used for the at-risk patients who are not suitable candidates for pharmacological thromboprophylaxis. The American College of Chest Physicians (ACCP) and American Academy of Orthopedic Surgeons (AAOS) have recently recommended aspirin as an option for VTE prophylaxis in patients undergoing total joint replacement;[7, 8] however, the quality grading recommendation for its use as monotherapy is not high enough.[8] After an acute VTE event, anticoagulation is commenced for the purposes of preventing death and recurrent VTE events

(secondary prevention). With regards to secondary prevention, guideline bodies such as the ACCP and the European Society of Cardiology (ESC) recommend anticoagulation for a period of at least 3 months after a first VTE event.[9, 10] In the acute phase of a VTE event, parenteral anticoagulants such as unfractionated heparin, LMWH, or fondaparinux are the cornerstones of treatment and used over a period of 5-10 days. Parenteral heparin or fondaparinux needs to overlap with the commencement of a vitamin K antagonist (VKA) (warfarin, acenocoumarol, or phenindione) preferably started on the same day as the parenteral anticoagulant or alternatively can be followed by administration of one of the NOACs such as edoxaban or dabigatran.[10] Though the optimal duration of anticoagulant therapy after a first VTE episode is still subject to debate; it has been argued that a period of 3-6 months is adequate. In some specific patient populations, secondary prevention is extended beyond the initial period (3-6 months) and may continue indefinitely as long as the benefit-risk balance is favourable.[10] Anticoagulant therapy constitutes a double-edged sword; though it is effective in the primary and secondary of VTE, it is an inconvenient therapy and associated with high risk of bleeding.[11] Despite substantial progress made in understanding the epidemiology of VTE and the availability of effective primary and secondary prevention prophylaxis, there has been no decrease in its incidence for the past several decades.[12] Venous thromboembolism remains a global public health problem.[2]

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (commonly known as statins), are well established for the primary and secondary prevention of cardiovascular disease (CVD) and this is based on their lipid-lowering properties.[13, 14, 15] Statins reduce lipids by inhibiting cholesterol biosynthesis and promoting low-density lipoprotein (LDL) clearance from the circulation. Beyond their lipid-lowering properties, statins are also known to have several pleiotropic effects and these include improving endothelial function, decreasing oxidative stress and inflammation, enhancing stability of atherosclerotic plaques, decreasing platelet activation, inhibiting thrombosis, and inhibition of smooth muscle proliferation (**Figure 1**).[16] There have been suggestions that statins via their ability to modulate coagulation and inflammation,[17] might play a potential role in reducing the incidence of VTE. The role of statins in the prevention of VTE is of immense clinical interest and the past decade has witnessed the publication of several studies to clarify the role of statins in

preventing VTE. Till recently, the findings on the benefits of statins in VTE prevention have been mostly conflicting.

This review summarizes the available epidemiological and interventional evidence till date on the role of statins in the prevention of VTE; the postulated biologic mechanisms underlying these associations; outlines areas of outstanding uncertainty; and the possible implications for future clinical practice.

2. Statins and primary prevention of VTE

The effect of statins on primary prevention of VTE was initially brought to light through the publication of findings from the Heart and Estrogen/progestin Replacement Study (HERS) in 2002.[18] This study was a randomized clinical trial to evaluate the effects of estrogen and progesterone supplementation on cardiovascular events (morbidity and mortality) in 2,763 postmenopausal women with coronary heart disease (CHD). In a nonrandomized comparison of statin versus nonstatin users, an approximately 50 percent risk reduction in VTE was reported. In 2009, the first randomized controlled trial (RCT) - the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - demonstrated that rosuvastatin significantly reduced the incidence of VTE.[19] This trial was based on 17,802 relatively healthy participants with high levels of high sensitivity C-reactive protein (hsCRP) and normal LDL-cholesterol levels. However, the few VTE events recorded suggested a statistical play of chance and this triggered calls for further studies to replicate these results.[20] Since the publication of these two landmark studies, several observational studies as well as RCTs have been published evaluating the role of statins in the primary prevention of VTE. Though a protective effect of statins on VTE risk has been suggested, the results of these studies have mostly been inconsistent. Given the inconsistency in the evidence, there were efforts to pool the evidence which resulted in a number of published reviews on the topic.[21, 22, 23] In an elegant meta-analysis of RCTs published in 2012, Rahimi and colleagues found no significant reduction in VTE events with statin therapy.[22] Given the publication of further trials after this study and the persisting uncertainty on the role of statins in the primary prevention of VTE, our group has recently published a comprehensive meta-analysis of 36 published studies (comprising

of 13 observational cohort designs and 23 RCTs) with data on more than 3.2 million participants.[24] In the observational studies, statin use was associated with a 25 percent reduced risk of VTE compared with no statin use. Similarly in RCTs, statin use reduced the risk of VTE compared with placebo by 15 percent (**Figure 2**). A subgroup analysis of our meta-analysis of RCTs showed that rosuvastatin was associated with the lowest risk of VTE (45 percent reduction) compared with other statins. Taking the all current evidence together, it can be suggested that statins may indeed have a true protective effect on VTE primary prevention.

3. Statins and secondary prevention of VTE

Patients with a first episode of VTE are at increased risk of recurrent episodes. The risk of VTE recurrence is said to vary with time after the first event; it is highest during the first 6-12 months, declines subsequently but never falls to zero.[25] Approximately 25 and 30 percent of patients with VTE experience a recurrence within 5 and 10 years respectively.[4, 26, 27] Although secondary prophylaxis is effective in the prevention of recurrence, patients with a first VTE are still at an elevated risk of a second episode. A recurrence rate of 3 percent has been reported during the first 3 to 6 months of anticoagulant therapy.[28, 29] It has been reported that beyond an initial 3 months of prophylactic anticoagulation, the duration of acute therapy does not influence the rate of VTE occurrence.[4] Some patients with a first VTE such as those whose VTE is cancer-related or those with an unprovoked or idiopathic PE, usually require an extended duration of anticoagulation because their overall risk of recurrent VTE is substantially increased.[30, 31] Apart from the need for frequent laboratory monitoring and dose-adjustments which is associated with long-term anticoagulation, there is an increased risk of major bleeding; reducing the risk of VTE recurrence with anticoagulant therapy has been associated with about a 5-fold increase of major bleeding.[32] Venous thromboembolism recurrence is a major clinical problem and of public health importance. Compared to primary prevention, the role of statin therapy in the secondary prevention of VTE is limited. Randomized controlled trials on the role of statin therapy in VTE recurrence are not available to make concrete conclusions about the value of statins in the secondary prevention of VTE. However, a number of observational studies have been conducted, but their results have been inconsistent.[33, 34] In a recent

pooled analysis of 8 available studies comprising of 103,576 participants and 13,168 recurrent VTE events,[35] our group has shown that statin use is associated with a reduced risk of recurrent VTE as well as DVT and PE (**Figure 3**). Secondary prevention of VTE may be another potential indication of statins; however, well-designed intervention studies are now needed to corroborate this evidence.

4. Postulated mechanisms

Several factors are implicated in the etiopathogenesis of VTE and these include alterations in blood flow and the coagulation cascade, endothelial dysfunction, and hypercoagulable states.[36] It has also been postulated that an inflammatory hypothesis may be involved, but the evidence is unclear and remains a subject of considerable debate.[37, 38] Inflammatory markers such as CRP are well known to be associated with an increased risk of atherothrombosis[39, 40] and may also promote hypercoagulable states, but whether inflammation actually increases the risk of VTE is not very certain.

Various mechanisms have been proposed to explain the protective effect of statins on the risk of VTE and these include (i) statins downregulate the blood coagulation cascade, leading to reduced tissue factor (TF) expression and which causes reduced thrombin formation;[41, 42, 43, 44] (ii) statins cause increased expression of thrombomodulin on the endothelial cells, which may enhance the activity of the protein C anticoagulation system, thereby inhibiting the coagulation cascade;[45] (iii) statins may decrease the susceptibility for thrombosis and coagulation, by decreasing plasminogen activator inhibitor-1 expression[46] and increasing tissue plasminogen activator; (iv) statins decrease the coagulant activities of factors VII and VIII and reduce factor XIII activation; [47] (v) statins have also been suggested to reduce the risk of VTE via reduction in plasma levels of D-dimer, enhanced fibrinolysis and inhibitory effects on platelet aggregation;[48, 49, 50] and (vi) statins may reduce the risk of VTE by modulating fibrin clot properties, which has been demonstrated in both healthy individuals and those with previous VTE;[51] indeed, a recent review has suggested that abnormalities in fibrin clot properties may contribute to the pathogenesis of VTE.[52] Statins may also reduce the risk of VTE by modulating the activity of FVIII.[53] It has been reported that the decrease in FVIII activity as a result of statin use, usually occurs in association with decreased levels

of von Willebrand factor.[54] Furthermore, the beneficial effects of statins on VTE have also been attributed to its anti-inflammatory effects.[55] Indeed, several inflammatory markers such as CRP, the interleukins, and tumour necrosis factor alpha have been shown to be associated with an increased risk of VTE.[56, 57, 58] Findings from the JUPITER trial demonstrated that 20 mg/day of rosuvastatin therapy in healthy men and women lowered hsCRP levels by 37 percent and resulted in an approximately 50 percent relative reduction in VTE risk.[19] Taking these results and the positive association between CRP and VTE risk, it has been suggested that some of the reduction in VTE risk by statins may occur as a result of reduction in inflammation.[59] Finally, though the VTE preventive effect of statins appears to be independent of their cholesterol lowering effects; whether this is really the case has been the subject of considerable debate.[60] Apart from the fact that arterial atherothrombosis and VTE are closely linked [61, 62, 63] and share common antecedent risk factors,[64] they also share common therapies for prevention and/or treatment which include aspirin, heparin, and warfarin.[60] Dyslipidemia, an established risk factor for arterial thrombosis, has also been implicated in the development of VTE.[60] Indeed, hypercholesterolemia has been shown to produce a procoagulant state[65] and is associated with platelet hyperactivity;[65, 66] which goes to suggest that statins may reduce the risk of VTE via lowering of lipid levels. However, emerging evidence suggests this is not the case. In the JUPITER trial, there was a substantial reduction in risk of VTE on administration of rosuvastatin to subjects with normal LDL but elevated levels of hsCRP.[19] The authors speculated that the reduction in thrombosis might be due to the inhibition of TF expression by statins, but this could not be proved in the trial. In a recent experimental study, Owens et al.[67] demonstrated that hypercholesterolemia causes a prothrombotic state via elevation in levels of oxidized LDL (oxLDL) in plasma which induces TF expression. The investigators also showed that simvastatin inhibited oxLDL induction of TF expression in animal and human cells and concluded that the ability of statins to reduce VTE in hypercholesterolemic patients might be via their ability to reduce TF expression. These multiple biological effects could potentially explain the protective effects of statins on the incidence of VTE; however, further study is still warranted.

5. Conclusions

Taking previous and the recent body of evidence together suggests that statins may have a potential role to play in both the primary and secondary prevention of VTE in addition to their established role in CVD prevention. Indeed, the extensive body of evidence may support a true protective effect on VTE. The question is should statins be prescribed solely to reduce the risk of VTE based on the current evidence? The answer is an emphatic no. Prevention of VTE may be another potential indication of statins; however, it is still too early to expand guidelines for statins use to include prevention of VTE. It should be borne in mind that there were some limitations to the two recent reviews on the role of statins in the primary and secondary prevention of VTE.[24, 35] In the meta-analysis of primary prevention of VTE,[24] the majority of trials included in the pooled analysis did not specify VTE as a primary endpoint, but recorded the incidence of VTE as adverse events. In the review of secondary prevention of VTE,[35] pooled analysis was based on a limited number of studies which were observational cohort designs. Interventional evidence is therefore needed to corroborate this finding. Indeed, further robust evidence is warranted to establish any potential true protective effect of statins on VTE. Furthermore, whether statins reduce the risk of VTE in high risk populations, such as patients who have had a lower limb total joint replacement, is uncertain at the moment; as the majority of primary prevention previous studies conducted on the topic have been mainly based in patients at low VTE risk and those with pre-existing CVD.[24] According to unpublished research presented at the 2014 Annual Meeting of the AAOS, in a retrospective cohort of patients who had undergone elective total knee and hip replacements, statins in addition to conventional VTE prophylactic therapy significantly reduced the risk for post-operative VTE events by 48 percent when compared with the non-statin group.[68] The authors also estimated that 14 joint replacement patients will need to be treated with statins to avoid one VTE event. Though statins may not be solely prescribed to reduce the risk of VTE based on the current evidence, guideline bodies should consider including statin therapy as an adjunct to anticoagulant therapy in VTE prevention in some specific patient populations. Despite anticoagulants being very effective for reducing the risk of VTE, they are commonly associated with increased risk of major haemorrhage which can be fatal. In

addition, high rates of VTE have still been reported in people who have received anticoagulant therapy. Since most patients who experience VTE generally tend to have prevalent medical conditions such as CHD and dyslipidaemia, the use of statins may be beneficial in the prevention of VTE and these comorbidities in combination. However, not everybody will agree to this recommendation for various reasons.

Though statins have been in use for several decades and the amount of evidence showing the beneficial effects of taking statins in cardiovascular prevention is substantial, there is still a lot of debate as to whether statins should be prescribed to everybody at high cardiovascular risk or not. It has been argued by some health professionals that the risks of statins outweigh the benefits for patients with lower cardiovascular risk. Cost implications have also been reported. Though side effects are generally associated with the use of statins, majority of these have been generated as a result of media hype. Statins are generally safe and well tolerated and published evidence suggests that only a small fraction of side effects reported by people are attributable to common doses of statins.[69] The most common and important adverse side effects of statins include muscle pain, an increased risk of diabetes, and increased blood levels of liver enzymes.[70, 71, 72] While the majority of people taking statins won't experience these side effects, muscle-related symptoms generally resolve rapidly once treatment is stopped.[72] The majority of people who develop early onset diabetes as a result of statin therapy are those people who are already at high risk. Moreover, most people with diabetes are also prescribed statins because of their high risk of developing CVD. Finally, statins are very cheap drugs as the majority are now off patent and compared with anticoagulants, statins do not cause an increased risk of bleeding.

6. Expert commentary

The broad body of evidence indicates that statins may play a potential role in the primary and secondary prevention of VTE in addition to their established role in CVD prevention. Further robust evidence however is needed to establish these roles. The evidence is much stronger for primary prevention, as a number of RCTs have been able to demonstrate a beneficial role of statins in VTE risk reduction. However, the findings from these trials could be biased as they were mostly based on

VTE collected as safety or adverse events. For secondary prevention, the evidence is limited and has been mostly based on analysis of administrative data. Further robust evidence in the form of well-designed large-scaled trials are needed to establish these potential additional roles of statins.

Intervention studies in very high-risk populations are also warranted. It has however been debated that such trials are unlikely to be feasible in the near future, since the number of patients needed to be recruited are prohibitively large.[73] There may be a challenge in conducting such trials, but this is not impossible. The Heart Protection Study of cholesterol lowering with simvastatin recruited over 20,000 high-risk individuals,[14] though it failed to demonstrate any protective effect of statins on VTE risk despite the relatively substantial number of VTE events recorded. It is uncertain why there was a lack of a protective effect, but this could be attributed to the type of statin used. Whether the effect of statins on VTE is a class effect is not clear, but recent evidence from a review showed that rosuvastatin (a newer type of statin) reduced the risk of VTE compared with other statins;[24] though a head-to-head comparison was not possible due to the limited data. Indeed, a number of studies have suggested that rosuvastatin is more effective at lowering LDL-cholesterol compared with other statins.[74, 75, 76] Future trials should also evaluate if the protective effect of statins is a class effect.

There is currently insufficient high quality evidence for guideline bodies to recommend the use of statins to replace anticoagulants in reducing the risk of VTE, especially in high-risk patients who require thromboprophylaxis with anticoagulants. However, in the absence of robust clinical trial evidence, relevant guideline bodies should review the overall body of evidence and consider including statin therapy as an adjunct to anticoagulant therapy in VTE prevention in some specific patient populations. Patient populations that may benefit from statin therapy as primary or secondary prophylaxis in addition to anticoagulant therapy are those at very high risk of a first or recurrent VTE, such as patients who have undergone major surgery such as lower limb total joint replacement, patients with active cancer with or without chemotherapy, patients with neurological disease with paresis of the lower limbs, as well as patients with a first unprovoked PE. Statins may be effective adjuncts to anticoagulant therapy in such patients as high VTE rates including fatal PE events are still reported in patients who have received anticoagulant therapy. As regards to the best time to commence treatment, statin therapy should always be initiated early as these drugs take a few weeks

to exhibit their effects. For example in patients who are about to have a low limb total joint replacement, statin therapy could be started 1-2 weeks before the surgery. Different statins vary in their potency and their onset of action, and therefore these factors need to be taken into account when initiating therapy.

Statin may be considered in place of anticoagulants in some patient populations who are not suitable candidates for anticoagulant therapy and patients who are at low risk of VTE to minimize the risk of bleeding associated with anticoagulant therapy; but this decision should be taken on an individual patient basis by the attending healthcare professional after careful evaluation of the risk profile of the patient and a trade-off between benefits and risks, particularly the risk of a VTE. In addition, other prophylactic measures such as enhancing mobility and the use of graduated compression stockings or lower extremity compression devices should be instituted in such patients. Instances where statins could be used instead of anticoagulants include (i) long-term primary prevention of VTE among patients undergoing ambulatory anti-cancer chemotherapy, who are at moderate risk of VTE and generally do not require anticoagulant prophylaxis, but have an elevated risk of major bleeding with anticoagulant therapy;^[77, 78] (ii) the secondary prevention of VTE following the completion of an initial course of anticoagulant therapy after an idiopathic VTE event; in this patient group, the risk of recurrence is at the highest in the first 3 months and subsequently declines after this period;^[60] (iii) patients with a first VTE provoked by transient or reversible factors such as immobilization, surgery, trauma, or HRT, as these patient populations have a lower risk of VTE recurrence;^[31] and (iv) patients who are at low VTE risk and have comorbidities such as CHD and dyslipidaemia. To re-iterate the point again, consideration of the use of statins without the need for anticoagulants should be decided on an individual basis after careful evaluation of the risk-benefit ratio.

7. Five-year view

The potential role of statins in the prevention of VTE is a subject of much debate and has important implications for clinical practice. In primary prevention, pooled evidence from several observational cohorts as well as interventional studies show that statins reduce the risk of VTE. In secondary

prevention, pooled limited observational evidence also suggests that statins may reduce VTE recurrence. However, based on the limitations of previous studies, there isn't enough robust evidence to inform major guideline recommendations.

In 5 years, it is expected that more robust large-scale studies will have further elucidated the beneficial role of statins in VTE prevention, especially for secondary prevention where the evidence is quite limited. Further studies clarifying the mechanistic pathways by which statins reduce the risk of VTE is also expected.

8. Key issues

- Observational and interventional studies indicate that statins may play a potential role in the primary prevention of VTE.
- A class effect of statins in the primary prevention of VTE is unclear because of limited evidence. However, existing evidence indicates that rosuvastatin substantially reduces VTE risk compared with other statins.
- Limited observational data suggests that statins may play a potential role in the secondary prevention of VTE.
- Well-designed large-scale trials are needed to confirm the role of statins in the primary and secondary prevention of VTE.
- Intervention studies are also needed in at high-risk VTE populations such as patients undergoing lower limb total joint replacement.
- Statins should not replace anticoagulants to reduce the risk of VTE. However, in the absence of robust evidence, guideline bodies should review the evidence and consider including statin therapy as an adjunct to anticoagulant therapy in VTE prevention in some specific patient populations, such as those at very high risk of VTE.
- Statin therapy instead of anticoagulants may be considered in patients who are not suitable candidates for anticoagulant therapy and in some populations who are at low VTE risk, to minimize the high bleeding risk associated with anticoagulant therapy. However, this needs to be

decided on an individual patient basis after careful evaluation of the risk profile of such patients and weighing the benefits against the risks.

Funding

This paper was not funded.

Financial and competing interests disclosure

The authors report no conflicts of interest

References

1. Heit JA. The epidemiology of venous thromboembolism in the community. *Arterioscler Thromb Vasc Biol.* 2008 Mar;28(3):370-2. PubMed PMID: 18296591.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost.* 2007 Oct;98(4):756-64. PubMed PMID: 17938798.
3. Wong P, Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism. *Phlebology.* 2012;27 Suppl 2:2-11. PubMed PMID: 22457300.
4. Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol.* 2015 Aug;12(8):464-74. PubMed PMID: 26076949.
5. Douketis JD, Gu CS, Schulman S, et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. *Ann Intern Med.* 2007 Dec 4;147(11):766-74. PubMed PMID: 18056660.
6. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet.* 2012 May 12;379(9828):1835-46. PubMed PMID: 22494827.
7. Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. *J Bone Joint Surg Am.* 2012 Apr 18;94(8):746-7. PubMed PMID: 22517391.
8. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012 Feb;141(2 Suppl):e278S-e325S. PubMed PMID: 22315265.
9. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008 Jun;133(6 Suppl):454S-545S. PubMed PMID: 18574272.
10. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J.* 2014 Nov 14;35(43):3033-69, 3069a-3069k. PubMed PMID: 25173341.
11. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. *Ann Intern Med.* 2003 Dec 2;139(11):893-900. PubMed PMID: 14644891.
12. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med.* 2005 Nov 15;143(10):697-706. PubMed PMID: 16287790.
13. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med.* 2008 Nov 20;359(21):2195-207. PubMed PMID: 18997196.

14. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002 Jul 6;360(9326):7-22. PubMed PMID: 12114036.
15. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014 Jul 1;63(25 Pt B):2889-934. PubMed PMID: 24239923.
16. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. *Am J Cardiol*. 2005 Sep 05;96(5A):24F-33F. PubMed PMID: 16126020.
17. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation [Review]. *Arteriosclerosis, Thrombosis & Vascular Biology*. 2005;25(2):287-94. PubMed PMID: 15569822.
18. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). *Circulation*. 2002;105(25):2962-7. PubMed PMID: 12081988
19. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. *N Engl J Med*. 2009 Apr 30;360(18):1851-61. PubMed PMID: 19329822.
20. Perez A, Bartholomew JR. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. *Cleve Clin J Med*. 2010 Mar;77(3):191-4. PubMed PMID: 20200169.
21. Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. *Thromb Res*. 2011 Nov;128(5):422-30. PubMed PMID: 21641019.
22. Rahimi K, Bhala N, Kamphuisen P, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. *PLoS medicine*. 2012;9(9):e1001310. PubMed PMID: 23028261.
23. Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. *Eur Heart J*. 2010 May;31(10):1248-56. PubMed PMID: 20031958.
24. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. *Lancet Haematol*. 2017 Jan 12. PubMed PMID: 28089655.
25. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med*. 1998 Mar 23;158(6):585-93. PubMed PMID: 9521222.
26. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med*. 1996 Jul 01;125(1):1-7. PubMed PMID: 8644983.
27. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med*. 2000 Mar 27;160(6):761-8. PubMed PMID: 10737275.

28. Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*. 2010 Dec 23;363(26):2499-510. PubMed PMID: 21128814.
29. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med*. 2009 Dec 10;361(24):2342-52. PubMed PMID: 19966341.
30. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012 Feb;141(2 Suppl):e419S-94S. PubMed PMID: 22315268.
31. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. *Arterioscler Thromb Vasc Biol*. 2009 Mar;29(3):298-310. PubMed PMID: 19228602.
32. Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. *BMJ*. 2013 Aug 30;347:f5133. PubMed PMID: 23996149.
33. Delluc A, Tromeur C, Le Moigne E, et al. Lipid lowering drugs and the risk of recurrent venous thromboembolism. *Thromb Res*. 2012 Dec;130(6):859-63. PubMed PMID: 22939687.
34. Biere-Rafi S, Hutten BA, Squizzato A, et al. Statin treatment and the risk of recurrent pulmonary embolism. *Eur Heart J*. 2013 Jun;34(24):1800-6. PubMed PMID: 23396492.
35. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. *Eur Heart J*. 2017 Mar 22. PubMed PMID: 28369602.
36. Kyrle PA, Eichinger S. Deep vein thrombosis. *Lancet*. 2005 Mar 26-Apr 1;365(9465):1163-74. PubMed PMID: 15794972.
37. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. *Thromb Haemost*. 2005 Aug;94(2):362-5. PubMed PMID: 16113826.
38. Lippi G, Favaloro EJ, Montagnana M, et al. C-reactive protein and venous thromboembolism: causal or casual association? *Clin Chem Lab Med*. 2010 Dec;48(12):1693-701. PubMed PMID: 20704541.
39. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med*. 1997 Apr 03;336(14):973-9. PubMed PMID: 9077376.
40. Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. *J Intern Med*. 2008 Oct;264(4):295-314. PubMed PMID: 18823504.
41. Ferro D, Basili S, Alessandri C, et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. *Atherosclerosis*. 2000 Mar;149(1):111-6. PubMed PMID: 10704621.
42. Baetta R, Camera M, Comparato C, et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid

- lowering. *Arterioscler Thromb Vasc Biol.* 2002 Apr 1;22(4):692-8. PubMed PMID: 11950712.
43. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. *Thromb Haemost.* 2002 Jul;88(1):41-7. PubMed PMID: 12152675.
 44. Arslan F, Pasterkamp G, de Kleijn DP. Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective. *Circ Res.* 2008 Aug 15;103(4):334-6. PubMed PMID: 18703784.
 45. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. *Circulation.* 2005 Aug 2;112(5):720-6. PubMed PMID: 16043642.
 46. Nishino M, Hoshida S, Kato H, et al. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. *Circulation journal : official journal of the Japanese Circulation Society.* 2008 Feb;72(2):232-7. PubMed PMID: 18219159.
 47. Sbarouni E, Melissari E, Kyriakides ZS, et al. Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease. *Am J Cardiol.* 2000 Jul 01;86(1):80-3. PubMed PMID: 10867097.
 48. Sahebkar A, Serban C, Mikhailidis DP, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. *Thromb Haemost.* 2015 Aug 31;114(3):546-57. PubMed PMID: 26017749.
 49. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. *Int J Cardiol.* 2000 Oct;76(1):23-32. PubMed PMID: 11121593.
 50. Undas A, Celinska-Lowenhoff M, Kaczor M, et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. *Thromb Haemost.* 2004 Jun;91(6):1065-77. PubMed PMID: 15175791.
 51. Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. *Thromb Haemost.* 2012 Jun;107(6):1180-2. PubMed PMID: 22371154.
 52. Undas A. Fibrin clot properties and their modulation in thrombotic disorders. *Thromb Haemost.* 2014 Jul 03;112(1):32-42. PubMed PMID: 24671700.
 53. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. *Drugs.* 2003;63(17):1821-54. PubMed PMID: 12921488.
 54. Bo M, Bonino F, Neirotti M, et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. *Angiology.* 1991 Feb;42(2):106-13. PubMed PMID: 2006757.
 55. Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. *Int Angiol.* 2007 Dec;26(4):306-11. PubMed PMID: 18091697.
 56. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. *Journal of thrombosis and haemostasis : JTH.* 2004 Apr;2(4):619-22. PubMed PMID: 15102017.

57. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. *Br J Haematol*. 2002 Jan;116(1):173-7. PubMed PMID: 11841414.
58. Kunutsor SK, Sameul S, Blom AW, et al. Serum C-reactive protein increases the risk of venous thromboembolism: A prospective study and meta-analysis of published prospective evidence *European Journal of Epidemiology*. 2017 (In Press).
59. Olson NC, Cushman M, Lutsey PL, et al. Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. *Journal of thrombosis and haemostasis : JTH*. 2014 Dec;12(12):1993-2001. PubMed PMID: 25292154.
60. Ray JG. Why might statins prevent venous thromboembolism: what needs to be done to know more? *Expert Opin Investig Drugs*. 2002 Nov;11(11):1659-68. PubMed PMID: 12437511.
61. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. *N Engl J Med*. 2003 Apr 10;348(15):1435-41. PubMed PMID: 12686699.
62. Sorensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. *Lancet*. 2007 Nov 24;370(9601):1773-9. PubMed PMID: 18037081.
63. Braekkan SK, Mathiesen EB, Njolstad I, et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. *Journal of thrombosis and haemostasis : JTH*. 2008 Nov;6(11):1851-7. PubMed PMID: 18665924.
64. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. *American journal of epidemiology*. 2005 Nov 15;162(10):975-82. PubMed PMID: 16207808.
65. Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. *Circulation*. 1995 Dec 01;92(11):3172-7. PubMed PMID: 7586300.
66. Kaul S, Waack BJ, Padgett RC, et al. Altered vascular responses to platelets from hypercholesterolemic humans. *Circ Res*. 1993 Apr;72(4):737-43. PubMed PMID: 8443865.
67. Owens AP, 3rd, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. *J Clin Invest*. 2012 Feb;122(2):558-68. PubMed PMID: 22214850.
68. Criner KT, Trionfo A, editors. Impact of Statins on Postoperative Venous Thromboembolic Events Following Total Knee and Hip Replacements. Annual Meeting of the American Academy of Orthopaedic Surgeons; 2014 March 11; New Orleans, Louisiana.
69. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. *Eur J Prev Cardiol*. 2014 Apr;21(4):464-74. PubMed PMID: 24623264.
70. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. *Circ Cardiovasc Qual Outcomes*. 2013 Jul;6(4):390-9. PubMed PMID: 23838105.

71. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. *Expert Opin Drug Saf*. 2012 Nov;11(6):933-46. PubMed PMID: 22866966.
72. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2016 Nov 19;388(10059):2532-2561. PubMed PMID: 27616593.
73. Gaertner S, Cordeanu EM, Nouri S, et al. Statins and prevention of venous thromboembolism: Myth or reality? *Arch Cardiovasc Dis*. 2016 Mar;109(3):216-22. PubMed PMID: 26778087.
74. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. *Curr Med Res Opin*. 2003;19(8):689-98. PubMed PMID: 14687438.
75. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med*. 2011 Dec 01;365(22):2078-87. PubMed PMID: 22085316.
76. Berne C, Siewert-Delle A, investigators Us. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. *Cardiovasc Diabetol*. 2005 Jun 03;4:7. PubMed PMID: 15935095.
77. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. *Medicine (Baltimore)*. 1999 Sep;78(5):285-91. PubMed PMID: 10499070.
78. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. *J Clin Oncol*. 2015 Feb 20;33(6):654-6. PubMed PMID: 25605844.

Figure Legends

Figure 1: Pleiotropic effects of statins

NO, nitric oxide; ROS, reactive oxygen species

Figure 2: Effect of statin therapy on primary prevention of venous thromboembolism in pooled analysis of randomized controlled trials

Reproduced with permission from Kunutsor et al., Lancet Haematol. 2017 Feb;4(2):e83-e93

CI, confidence interval; RR, relative risk

Figure 3: Association of statin use with risk of recurrent venous thromboembolism in pooled analysis of observational cohort studies

Reproduced with permission from Kunutsor et al., Eur Heart J. 2017 May 21;38(20):1608-1612

CI, confidence interval; RR, relative risk